

EXSERVAN ORAL FILM (riluzole)

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Exservan (riluzole) is an oral film indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS) (1). It is thought that Exservan modulates the actions of glutamate. The mechanism by which this happens is not clearly known but may include direct effects on the neurotransmitter itself and target receptors, the inhibition of glutamate release, blockade or inactivation of voltage-dependent sodium channels that are important for glutamate release, interference with intracellular events that result from binding of glutamate to receptors, and/or inhibition of arachidonic acid metabolism (2). Glutamate is a neurotransmitter (cell-signaling molecule) thought to rise to toxic levels in the brain and spinal cord of ALS patients, damaging nearby nerve cells. By reducing the buildup of glutamate, it is thought that Exservan prevents or slows the glutamate-induced deterioration of motor neurons (3).

Regulatory Status

FDA-approved indication: Exservan is indicated for the treatment of amyotrophic lateral sclerosis (ALS) (1).

Studies have shown that riluzole is safe and effective for slowing disease progression to a modest degree in ALS. Riluzole is considered first-line therapy along with nutritional supplements for patients with ALS (4).

Exservan can cause hepatic injury. Asymptomatic elevations of hepatic transaminases have also been reported. The use of Exservan is not recommended if patients develop hepatic transaminases levels greater than five times the upper limit of normal. Patients should be monitored for signs and symptoms of hepatic injury, every month for the first 3 months of treatment, and periodically thereafter (1).

The use of Exservan can result in neutropenia. Cases of severe neutropenia within the first 2 months of riluzole treatment have been reported. Patients should be advised to report febrile illnesses (1).

EXSERVAN ORAL FILM (riluzole)

Exservan can cause interstitial lung disease, including hypersensitivity pneumonitis. Exservan should be discontinued immediately if interstitial lung disease develops (1).

The safety and effectiveness of Exservan in pediatric patients less than 18 years of age have not been established (1).

Summary

Exservan (riluzole) is an oral film indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS) (1). It is thought that Exservan modulates the actions of glutamate. The mechanism by which this happens is not clearly known but may include direct effects on the neurotransmitter itself and target receptors, the inhibition of glutamate release, blockade or inactivation of voltage-dependent sodium channels that are important for glutamate release, interference with intracellular events that result from binding of glutamate to receptors, and/or inhibition of arachidonic acid metabolism (2). The safety and effectiveness of Exservan in pediatric patients less than 18 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Exservan while maintaining optimal therapeutic outcomes.

References

1. Exservan [package insert]. Warren, NJ: Aquestive Therapeutics; April 2021.
2. Riluzole Mechanism of Action. *Clinical Pharmacology*.
3. Maragakis NJ, Galvez-Jimenez N, et al. Epidemiology and pathogenesis of amyotrophic lateral sclerosis. UpToDate. Waltham, MA: UpToDate Inc.
4. Galvez-Jimenez N, Goyal NA, et al. Practice Parameter update: Disease-modifying treatment of amyotrophic lateral sclerosis. UpToDate. Waltham, MA: UpToDate Inc.